Filing Flows › Altimmune (ALT) › Q3 2025
Altimmune (ALT) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Altimmune (ALT) reported revenue of $5K for the third quarter 2025 (Q3 2025), 0% from a year earlier and 0% from the quarter before.
Altimmune, Q3 2025: revenue $5K (0% year over year), net loss $19.0M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5K | 0% | 0% |
| Operating profit | −$20.9M | — | — |
| Net earnings | −$19.0M | — | — |
| Operating cash flow | −$11.9M | — | — |
What changed
Revenue was $5K in Q3 2025, roughly flat year over year and roughly flat from the previous quarter.
Operating costs exceeded revenue by $20.9M, an operating margin of -417180.0%. Total costs fell 16% while revenue was flat. The fastest-growing cost line was General & admin (+19%). The quarter ended with a net loss of $19.0M, narrower than the previous quarter's $22.1M loss.
Operating cash flow was −$11.9M. Non-cash charges added back $27K of depreciation and $3.6M of share-based compensation. Working capital and other items added $3.5M.
Questions
What was Altimmune's revenue in the third quarter 2025?
Altimmune (ALT) reported revenue of $5K for the third quarter 2025 (Q3 2025), 0% from a year earlier and 0% from the quarter before.
Source: Altimmune 10-Q on SEC EDGAR.